Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.63 |
| ▸ | LPL | P06858 | 7/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | F9 | P00740 | 2/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631781 | 0.86 | LIPG (0.60) | LIPGLPLPDGFRBKDRSNCA | |
| SCHEMBL15481254 | 0.86 | LIPG (0.60) | LIPGLPLPDGFRBKDRSNCA | |
| SCHEMBL20984001 | 0.84 | LIPG (0.61) | LIPGLPLPDGFRBKDRSNCA | |
| SCHEMBL19107132 | 0.83 | LIPG (0.86) | LIPGLPLP4HB | |
| SCHEMBL17539929 | 0.83 | LIPG (0.86) | LIPGLPLP4HB | |
| SCHEMBL15458626 | 0.83 | LIPG (0.86) | LIPGLPLP4HB | |
| SCHEMBL20984011 | 0.82 | LIPG (0.51) | LIPGLPLPDGFRBKDRF9 | |
| SCHEMBL26432745 | 0.82 | LIPG (0.85) | LIPGLPLSNCAESR1ESR2 | |
| SCHEMBL18270361 | 0.81 | LIPG (0.83) | LIPGLPLP4HB | |
| SCHEMBL22214718 | 0.81 | LIPG (0.50) | LIPGLPLPDGFRBKDRSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109791984-B | Material for photoelectric conversion element for imaging element and photoelectric conversion element containing same | 日本化药株式会社 | 2023-02-07 | — | — | CN | disclosed |
| US-11374044-B2 | Material for photoelectric conversion element for use in imaging element, and photoelectric conversion element including same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2022-06-28 | — | — | US | disclosed |
| US-20190157321-A1 | Material for Photoelectric Conversion Element for Use in Imaging Element, and Photoelectric Conversion Element Including Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11374044-B2 | Material for photoelectric conversion element for use in imaging element, and photoelectric conversion element including same | SLC19A1, SLC46A1, SLC19A2 | LIPG 1535/4885LPL 2997/4885PDGFRB 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.